Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow JAGX by emailGet an email when JAGX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about JAGX, unsubscribe in one click. Privacy
📣 What JAGX Says Is Next
first half of 2027 · “Jaguar is targeting Breakthrough Therapy designation for crofelemer for the indication of microvillus inclusion disease (MVID), with a planned filing of an NDA (New Drug Application) with the U.S. Food and Drug Administration (FDA) for this indication in the first half of 2027.” MVID is a lethal and ultrarare genetic pediatric disorder that causes intestinal failure.”
Company press release, Jun 25, 2026 · SEC filing
mid-2027 · “We continue to sharply focus on our pivotal-stage development program for our novel proprietary powder-for-oral-solution formulation of crofelemer for rare intestinal failure indications, targeting an NDA in mid-2027, and on identifying a development and commercialization partner for this program.””
Company press release, May 27, 2026 · SEC filing
first half of 2027 · “Jaguar is targeting Breakthrough Therapy designation for crofelemer for the indication of microvillus inclusion disease (MVID), with a planned filing of an NDA (New Drug Application) with the U.S. Food and Drug Administration for this indication in the first half of 2027.”
Company press release, Feb 18, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full JAGX picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for JAGX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.